Information Provided By:
Fly News Breaks for August 13, 2019
ABEO
Aug 13, 2019 | 09:46 EDT
RBC Capital analyst Kennen MacKay lowered his price target on Abeona Therapeutics to $16 after its Q2 earnings miss, also reflecting the delay in its EB-101 program and changing in his valuation methodology to discounted cash flow model. The analyst is keeping his Outperform rating on the stock longer term however with a positive view of its in-house manufacturing capabilities and the clinical profile of EB-101.
News For ABEO From the Last 2 Days
There are no results for your query ABEO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.